Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors

Published:2016-07 Issue:1-2 Volume:509 Page:178-187
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Kibria Golam,Hatakeyama Hiroto,Sato Yusuke,Harashima Hideyoshi

Funder

Special Education and Research Expenses of the Ministry of Education

Culture, Sports, Science and Technology of Japan (MEXT)

Nagai Foundation, Tokyo

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference42 articles.

1. Liposomal drug delivery systems: from concept to clinical applications;Allen;Adv. Drug Deliv. Rev.,2013

2. Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells;Arora;Cancer Res.,2012

3. Doxil(R)–the first FDA-approved nano-drug: lessons learned;Barenholz;J. Control. Release,2012

4. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery;Bedu-Addo;Pharm. Res.,1996

5. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib;Broxterman;Drug Resist. Update.,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AN UPDATED REVIEW OF STEALTH LIPOSOMES AND ITS ABILITY TO EVADE THE IMMUNE SYSTEM: A NEW FRONTIER IN CANCER CHEMOTHERAPY;International Journal of Applied Pharmaceutics;2024-05-07

2. Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer;Molecules;2024-02-29

3. Nanocarrier-Based Localized and Effective Treatment of Renal Disorders: Currently Employed Targeting Strategies;Nanomedicine;2024-01-31

4. Liposome stability and integrity;Liposomes in Drug Delivery;2024

5. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming;Molecular Aspects of Medicine;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3